L-dopa-induced dyskinesia-clinical presentation, genetics, and treatment
International Review of Neurobiology. 2011-01-01; : 31-54
DOI: 10.1016/B978-0-12-381328-2.00002-X
Read on PubMed
1. Int Rev Neurobiol. 2011;98:31-54. doi: 10.1016/B978-0-12-381328-2.00002-X.
l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment.
Prashanth LK(1), Fox S, Meissner WG.
Author information:
(1)Morton & Gloria Shulman Movement Disorders Center, and Division of Neurology,
University of Toronto, Toronto Western Hospital, 399, Bathurst Street, Toronto,
Ontario, Canada M5V 2S8.
Levodopa-induced dyskinesia (LID) has been recognized since the introduction of
levodopa for the management of Parkinson’s disease (PD) and continues to be one
of the most clinically challenging factors in long-term management of patients
with PD. Most patients develop LID within 10 years of PD onset and the cause has
been attributed to various factors including disease demographics,
pharmacological, and possibly genetic causes. The clinical pattern of LID varies
and shows intra and inter-patient variability and has been classified based upon
phenomenology and relation to timing of levodopa. The potential armamentarium to
address and manage LID has significantly increased in the last decade. This
chapter addresses the current understanding of various clinical aspects and
available therapeutics for LID.
Copyright © 2011 Elsevier Inc. All rights reserved.
DOI: 10.1016/B978-0-12-381328-2.00002-X
PMID: 21907082 [Indexed for MEDLINE]